CDKN2A and melanoma: Likewise, NR2F6 ablation in the YUMM1.7(BrafV600E/Pten−/−/CDKN2A−/−) melanoma line attenuated tumor formation in immune-competent but not immune-incompetent mice (Fig. 2, G to I, and fig.